IBIO Latest Press Releases

-- March 9, 2026 --

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss Globe Newswire 7:00 AM

-- February 24, 2026 --

iBio to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- February 10, 2026 --

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- January 9, 2026 --

iBio Announces $26 Million Private Placement Globe Newswire 7:00 AM

-- November 24, 2025 --

iBio to Participate in the 8th Annual Evercore Healthcare Conference Globe Newswire 4:15 PM

-- November 12, 2025 --

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- October 30, 2025 --

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance Globe Newswire 7:00 AM

-- October 23, 2025 --

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Globe Newswire 7:00 AM

-- October 21, 2025 --

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek and PEGS Europe 2025 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software